Rise Advisors’s Royalty Pharma RPRX Stock Holding History

Rise Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-29	Closed	-$1.03K	–	780
2023 Q1	$1.03K	Hold	29	–	–	﹤0.01%	654
2022 Q4	$1.13K	Buy	29 +1	+4%	+$42	﹤0.01%	637
2022 Q3	$1K	Hold	28	–	–	﹤0.01%	669
2022 Q2	$1K	Hold	28	–	–	﹤0.01%	668
2022 Q1	$1K	Hold	28	–	–	﹤0.01%	630
2021 Q4	$1.12K	Buy	+28	New	+$1.09K	﹤0.01%	594

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rise Advisors's RPRX Position: Q2 2023 in Review

Rise Advisors sold out of Royalty Pharma (RPRX) in Q2 2023, closing a stake of 29 shares — an estimated $1.03K sold.

Rise Advisors first reported a position in RPRX in Q4 2021 and held it in 6 quarters. The position peaked at $1.13K in Q4 2022. 325 funds tracked by Wall St. Rank hold RPRX as of Q2 2023.

Rise Advisors reported no remaining Royalty Pharma position as of Q2 2023 after selling out during the quarter.
Rise Advisors sold 29 Royalty Pharma shares in Q2 2023, an estimated $1.03K.
Rise Advisors first reported a position in Royalty Pharma in Q4 2021 and held it in 6 quarters.
Rise Advisors's Royalty Pharma position peaked at $1.13K in Q4 2022.
325 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2023.

Based on Rise Advisors's 13F filing for Q2 2023, filed 10 Jul 2023.